Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio Medica LaboratoriesNSE:BMLL +1.21%18 Net Debt Paydown Yield % is 0% as of Aug. 13, 2026. GuruFocus rates NSE:BMLL with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 769 Medical Devices & Instruments companies, Bio Medica Laboratories ranks worse than 75.03% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Bio Medica Laboratories's Net Debt Paydown Yield % was 0%.
Bio Medica Laboratories (NSE:BMLL) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Bio Medica Laboratories Net Debt Paydown Yield % Related Terms
Bio Medica Laboratories Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Bio Medica Laboratories's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories Net Debt Paydown Yield % Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
Net Debt Paydown Yield %
0.00
0.00
0.00
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
Net Debt Paydown Yield %
0.00
0.00
0.00
NSE:BMLL vs ISRG, BDX, MDLN: Net Debt Paydown Yield % Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Bio Medica Laboratories (NSE:BMLL) has a Net Debt Paydown Yield % of 0% as of Aug. 13, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Bio Medica Laboratories and its competitors. According to the industry distribution chart, Bio Medica Laboratories ranks #577 out of 769 companies in the Medical Devices & Instruments industry, placing it in the top 75%.
Is Bio Medica Laboratories' Net Debt Paydown Yield % too high?
Bio Medica Laboratories' current Net Debt Paydown Yield % is 0%. Based on the distribution chart, Bio Medica Laboratories ranks #577 out of 769 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' Net Debt Paydown Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #577 out of 769 companies for Net Debt Paydown Yield %. This places Bio Medica Laboratories in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
The median Net Debt Paydown Yield % among Medical Devices & Instruments companies is 0.01, based on 769 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Net Debt Paydown Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current Net Debt Paydown Yield % is 0%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current Net Debt Paydown Yield % of 0%. The current Net Debt Paydown Yield % is 0%. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current Net Debt Paydown Yield % is 0% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score
Get the complete analysis for NSE:BMLL
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 
